MétaCan
Menu
Back to cohort

P-078 Enteral Feeding Therapy for Maintaining Remission in Crohnʼs Disease

2016· article· en· W2319389995 on OpenAlexaff
Wael El‐Matary, Anthony Otley, Jeff Critch, Ahmed M Abou-Setta

Bibliographic record

VenueInflammatory Bowel Diseases · 2016
Typearticle
Languageen
FieldBiochemistry, Genetics and Molecular Biology
TopicInflammatory Bowel Disease
Canadian institutionsMemorial University of NewfoundlandDalhousie UniversityUniversity of Manitoba
Fundersnot available
KeywordsMedicineInternal medicineRandomized controlled trialCrohn's diseaseCochrane LibraryEnteral administrationParenteral nutritionObservational studyCohort studyPediatricsDiseaseMEDLINE

Abstract

fetched live from OpenAlex

Exclusive Enteral nutrition (EN) therapy can be utilized as a primary treatment for active Crohn's disease (CD) and is considered as the first-line of treatment for CD in children, especially in Europe and Japan. The efficacy of supplementary EN for maintaining remission in patients with inactive CD is unclear. The aim of this work was to systematically identify, review and critically appraise the evidence of the efficacy and safety of EN in maintaining remission for patients with inactive CD. We searched PubMed/MEDLINE (National Library of Medicine), EMBASE (Ovid), and Cochrane Central Register of Controlled Trials (CENTRAL, Wiley) from inception till April 2015 for relevant citations of published randomized controlled trials (RCT) and cohort studies using individualized search strategies prepared for each database. The primary outcome was relapse rate in patients with inactive CD who have been in medically induced remission and subsequently started or maintained on EN for maintaining remission. Twelve studies, included 1169 patients, fulfilled the inclusion criteria with 3 adult RCTs and 2 pediatric observational studies included. Out of 730 patients who were given supplementary EN to maintain remission, 341 (46.7%) (95% CI 42.4%–49.6%) patients experienced first relapse compared to 281 (64%) (95% CI 59.5%–68.4%) out of 439 patients in the non-EN group (P < 0.01). The adult studies included 1074 patients with inactive Crohn's disease. The crude pooled relapse rate in the EN group was 47% (95% CI 43.3%–50.7%) compared to 64% (95% CI 59.2%–68.8%) in the non-EN group (P < 0.01). Only one high-quality adult RCT was found with a relapse rate of 34.5% in the EN group compared to 64% in the regular diet group (P < 0.01) after a mean duration of follow up of 11.9 months. For the 2 pediatric observational studies, the crude pooled relapse rate in the EN group was 42% (95% CI 27.2%–56.8%) compared to 63.5% (95% CI 49.9%–76.1%) in the non-EN group (P = 0.04). Although lack of compliance with EN intake was documented in few studies, no major adverse events were reported in patients taking EN. Compared to regular diet, the current evidence suggests that EN is safe and effective in maintaining remission for patients with inactive CD. Large properly designed randomized controlled studies are required to confirm the efficacy of supplementary enteral nutrition compared to individual medications such as immunomodulators and biological medications in maintaining remission in CD.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.003
metaresearch head score (Gemma)0.009
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: none
Teacher disagreement score0.011
Threshold uncertainty score0.036

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0030.009
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0020.003
Bibliometrics0.0040.003
Science and technology studies0.0000.001
Scholarly communication0.0010.001
Open science0.0010.001
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0110.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.010
GPT teacher head0.255
Teacher spread0.245 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2016
Admission routes1
Has abstractyes

Explore more

Same venueInflammatory Bowel DiseasesSame topicInflammatory Bowel DiseaseFrench-language works237,207